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Background. Assessing health-related quality of life
(HRQOL) can provide information on the types and degrees
of burdens that afflict patients with chronic medical conditions,
including end-stage renal disease (ESRD). Several studies have
shown important international differences among ESRD pa-
tients treated with hemodialysis, but no studies have compared
these patients’ HRQOL. Our goal was to document interna-
tional differences in HRQOL among dialysis patients and to
identify possible explanations of those differences.
Methods. We examined data from the Dialysis Outcomes
and Practice Patterns Study (DOPPS), a prospective, obser-
vational, international study of hemodialysis patients. We per-
formed a cross-sectional analysis of DOPPS data from the
United States, five countries in Europe (France, Germany,
Italy, Spain, and the United Kingdom), and Japan. Linear
mixed models were used to analyze differences in HRQOL,
using the KDQOL-SFTM. Norm-based scores were used to mini-
mize cultural response bias. Linear regression analysis was used
to adjust for confounding factors. Other variables included
demographic variables, comorbidities, primary cause of ESRD,
complications of ESRD and treatment, and socioeconomic status.
Results. In all generic HRQOL subscales, patients on all
three continents had much lower scores than their respective
population norm values. Patients in the United States had the
highest scores on the mental health subscale and the highest
mental component summary scores. Japanese patients reported
better physical functioning than did patients in the United
States or Europe, but they also reported the greatest burden
of kidney disease. Overall, these differences remained even
after adjusting for possible confounders.
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Conclusion. On all three continents, ESRD and hemodialy-
sis profoundly affect HRQOL. In the United States, the effects
on mental health are smaller than in other countries. Japanese
hemodialysis patients perceived that their kidney disease im-
poses a greater burden, but their physical functioning was sig-
nificantly higher. Different distributions of socioeconomic fac-
tors and major comorbid conditions could explain little of this
difference in physical functioning. Other possible factors, such
as quality of dialysis and related health care, deserve careful
study.
Advances in dialysis treatment have contributed to
improved survival of patients with end-stage renal dis-
ease (ESRD). However, despite improvements in the
treatment of ESRD, the level of health-related quality
of life (HRQOL) is much lower for these patients than
for the general population [1–3]. The assessment of
HRQOL can help identify ways to improve the well-
being of ESRD patients and potentially identify strate-
gies to prevent adverse outcomes. It has been shown,
for example, that HRQOL is a reliable and responsive
measure of the effectiveness of renal anemia treatment
[4]. Moreover, the evaluation of HRQOL may help iden-
tify an individual’s risk of death and hospitalization [5–7].
The incidence, prevalence, and distribution of causes
of ESRD have been shown to differ among dialysis cen-
ters in Japan, Europe, and the United States [8]. Numer-
ous studies have also documented international variation
in patient survival, compliance, withdrawal from dialysis,
and the patterns of medical practice related to ESRD
[9–12]. For example, the survival of ESRD patients is
much higher and the withdrawal rate is lower in Japan
than in Europe or the United States. [12] To date, how-
ever, no studies have compared data on HRQOL of
hemodialysis patients in these different regions. In this
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paper, we examined data from the Dialysis Outcomes
and Practice Patterns Study (DOPPS), a prospective,
observational, international study of hemodialysis pa-
tients. We sought to evaluate HRQOL among hemodial-
ysis patients in five European countries (France, Ger-
many, Italy, Spain, and the United Kingdom), the United
States, and Japan. We also investigated variables that
could explain similarities or differences in HRQOL
among dialysis patients treated in different countries.
METHODS
Design
This paper is based on cross-sectional observational
analyses of data from DOPPS, an international, prospec-
tive, observational study of hemodialysis practice pat-
terns and associated outcomes [13, 14]. The study is on-
going in the United States, five countries in Europe
(France, Germany, Italy, Spain, and the United King-
dom; known collectively as the Euro-DOPPS countries),
and Japan. The study was recently expanded to include
Australia, Belgium, Canada, New Zealand, and Sweden,
but not enough data have yet been collected from these
countries to be included in the present analysis. The
DOPPS investigates four major outcomes (mortality,
hospitalization, quality of life, and vascular access), using
the same questionnaires in each country. The design of
the DOPPS has been published previously [13].
Sampling and data collection
The dialysis facilities included in DOPPS are nation-
ally representative and patients are replaced when they
die or leave the facilities. Random samples of 20 to 40
hemodialysis patients were selected from each facility.
At study entry a medical questionnaire completed by
the nurse coordinator in the dialysis unit provided infor-
mation about the patients and the practice pattern of
the facility. Within 60 days of completion of the medical
questionnaire, the study participants filled out a patient
questionnaire, which included the questions of the Kid-
ney Disease Quality of Life Short Form (KDQOL-SFTM).
HRQOL data were obtained from approximately 60%
of the eligible patients. Translated versions of the
KDQOL-SF were used in Japan and the European coun-
tries. The questionnaire was generally self-administered;
therefore, healthier patients were more likely to com-
plete the questionnaire, which might have biased the
sample toward healthier respondents. However, a study
of the characteristics of nonrespondents showed no clini-
cally important bias.
Outcome and predictor variables
The KDQOL-SF includes both general measures and
measures specific to patients with kidney disease. The
general measures were based on questions from the 36-
item Short-Form Health Survey (SF-36), developed by
Ware and Sherbourne [15]. Previous data support the
use of the SF-36 and the KDQOL-SF as research instru-
ments to HRQOL [15–20]. The SF-36 Health Survey
was translated into Japanese and many other languages,
and national-norm data for Japan and for many other
countries are available from the International Quality
of Life Assessment project (IQOLA) [21]. The internal
consistency and reliability are similar among translations
of the SF-36 and the KDQOL-SF [19–29]. Patient re-
sponses to the SF-36 questions were used to determine
scores for the mental component summary (MCS) and
the physical component summary (PCS). The scales for
MCS and PCS are derived from eight different subscales:
physical functioning role (physical, bodily pain, general
health, and vitality) and social functioning role (emo-
tional, and mental health) [30].
The KDQOL-SF includes questions that supplement
the SF-36. These additional questions were designed to
assess the particular health-related concerns of individu-
als with kidney diseases and ESRD patients treated by
dialysis [16]. The kidney disease component summary
(KDCS) score, which corresponds to the MCS and PCS
of the SF-36, is derived from 11 subscales: symptoms/
problems, effects of kidney disease on daily life, burden
of kidney disease, work status, cognitive function, quality
of social interaction, sexual function, sleep, social sup-
port, dialysis staff encouragement, and patient satisfac-
tion.
We examined scores on all eight subscales of the SF-36
and the 11 subscales related to KDCS. Scores on each
of the 11 kidney disease–targeted subscales were exam-
ined, as was an average of the 11 scores. Many patients
did not answer questions on the sexual-functioning scale,
and in those cases the average of kidney disease–targeted
scale scores was the average of the remaining 10 scores.
The SF-36 and kidney disease–targeted portions of the
questionnaire were scored according to the manual by
Ware et al [31] and the KDQOL scoring manual [16].
On all scales, the possible scores range from 0 to 100;
higher scores indicate more or better functioning, or
better quality of life. The summary scales have the same
interpretation, but do not span the entire 0 to 100 range.
Demographic and comorbidity data were abstracted
from patients’ medical records at their entry into the
study. This baseline information included age, gender,
race, primary cause of ESRD, hematocrit, number of
years on dialysis, complications of ESRD, annual house-
hold income, employment status, and 15 comorbidities.
The comorbidities examined were coronary artery dis-
ease, congestive heart failure, other cardiac conditions,
hypertension, cerebrovascular disease, peripheral vas-
cular disease, diabetes (primary or contributing), lung
disease, cancer (other than skin cancer), HIV/AIDS,
gastrointestinal bleeding, neurological disease, recurrent
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cellulitis/skin infection, and dyspnea. The common com-
plications of ESRD that were examined included carpal
tunnel syndrome, amyloidosis (2-microglobulin), and
parathyroidectomy.
To take into account the facts that SF-36 scores vary
with age and with gender, and that those variations could
differ between countries, SF-36 scores were adjusted for
each country’s general population data. Details of this
norm-based scoring have been described elsewhere [22].
Scoring each country’s patient data on the basis of that
country’s general population data is also useful for an-
other reason: If people of different countries or cultures
are asked to judge, for example, the painfulness of the
same painful stimulus, the average responses could differ
between groups. Norm-based scoring can minimize this
“cultural response bias.” As part of the IQOLA project,
SF-36 data were collected from representative samples
of the general populations of many countries, including
the United States, the Euro-DOPPS countries, and Ja-
pan. Norm-based scoring of the questions targeting kid-
ney disease was not possible, because these measures
are meaningful to patients only, not to all members of
the general population.
Statistical analysis
Analyses included simple means and frequencies for
the crude baseline scores. Linear mixed models were
used to take into account possible influences on the com-
parisons of HRQOL scores among continents, including
the effects of demographic characteristics, comorbidities,
cause of ESRD, hematocrit, time on dialysis, employ-
ment status, and annual household income. Sensitivity
analyses were conducted to investigate the choice of
adjustment variables. Adjustments were made for pa-
tient hematocrit and into possible interactions with a
patient’s working status. We investigated an interaction
between working status and continent of residence. Fi-
nally, we investigated an interaction between working
and age.
We also used the linear mixed models to determine
adjusted HRQOL scores and to compare average values
among the continents, taking into account clustering at
the facility level. Mixed models were also used to com-
pare simple means among the continents, adjusting for
facility clustering. All statistical analyses were performed
with SAS, version 8.2 [SAS, Inc., Cary, NC, USA].
RESULTS
A total of 7378 patients were included in the analyses,
including 2406 patients in Europe, 2087 patients in Japan,
and 2885 patients in the United States. Overall, the aver-
age age was 59.4 years and the percentage of males was
57.3%. Table 1 lists factors considered likely to be associ-
ated with HRQOL. Almost all the comorbid conditions
were most common among the United States patients
and least common among the Japanese patients. A nota-
ble exception was diabetes, which was least common
among the Euro-DOPPS patients. Overall, the Japanese
patients were most likely to have been receiving dialysis
for at least 4 years. High annual incomes were most
common among the Japanese patients and least common
among the Euro-DOPPS patients. Both unemployment
and disability were most common among the United
States patients and least common among the Japanese
patients.
Table 2 shows the unadjusted and adjusted HRQOL
scores for the three DOPPS continents. Japanese pa-
tients had the best physical functioning; their scores were
markedly higher than those of patients on the other
continents, by almost 20 points. The scores for MCS
and mental health were significantly higher for patients
treated in the United States than in Europe. The scores
were also higher for United States patients than for Japa-
nese patients, although this difference was not statisti-
cally significant. Together with their apparently high
level of physical functioning, Japanese patients reported
the greatest burden of kidney disease: Before the scores
on the “burden” scale of the KDQOL were adjusted for
the factors in Table 1, they were much lower in Japan
than in the United States and the Euro-DOPPS coun-
tries; after adjustment for the covariates, the differences
between continents maintained the same direction and
were even larger.
Our sensitivity analyses revealed an interaction be-
tween working status and continent of residence. Among
the 22 HRQOL scales, this interaction was important
for only six scales in Europe and four scales in Japan.
Therefore, the interactions were not used as overall ad-
justments. When significant, the interaction was in the
direction of higher HRQOL for working patients in Eu-
rope and Japan compared to working patients in the
United States. In examining the interaction between
working and age, we did not see overwhelming evidence
to adjust all the models (four out of 22 scales). This
interaction, when significant, pointed to a reduced posi-
tive association between working and HRQOL as pa-
tients aged.
Table 3 shows the norm-based scoring of the SF-36
from the three continents, including the differences be-
tween the scores of hemodialysis patients and the popu-
lation norm score divided by one standard deviation of
the population. This table also shows the results from
linear regression analysis, including comorbid conditions
as additional independent variables. Age and gender
were also included in this model. The difference between
physical functioning of Japanese hemodialysis patients
and those in other countries was smaller than that shown
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Table 1. Mean demographic results, comorbid conditions, and clinical and socioeconomic variables
Characteristic Europe Japan United States
Sample size number 2406 2087 2885
Age years 59.9 58.4a 59.6
Male % 57.9 62.6a 52.8a
Black % 1.6 0.0 39.0b
Comorbidities %
Coronary artery disease 28.7 18.7b 48.3b
Congestive heart failure 24.1 5.6b 43.9b
Other cardiac problem 36.2 23.9b 34.6
Hypertension 72.5 56.1b 83.7b
Peripheral vascular disease 22.0 10.9b 24.3
Cerebrovascular disease 13.2 11.8 16.8a
Diabetes (primary or contributing) 19.3 25.4a 44.4b
Lung disease 10.7 1.2b 12.2
Cancer (other than skin) 9.0 5.1b 9.2
HIV/AIDS 0.2 0.0 1.1a
Gastrointestinal bleeding 5.2 3.3a 8.9b
Neurological disease 5.4 3.5a 11.1b
Psychiatric disorder 23.9 2.2b 22.6
Recurrent cellulitis 6.2 1.9b 10.0b
Dyspnea 18.9 2.4b 27.5a
Primary cause of ESRD %
Diabetes 13.8 22.4 36.6
Glomerulonephritis 16.2 54.7 11.9
Hypertension 10.5 3.6 28.9
Other 59.5 19.3 22.6
Hematocrit % (mean and SD) 32.5 (5.2) 30.1 (4.2)b 32.9 (4.7)
Years on dialysis %
1 22.6 11.0 29.3
1–3 37.2 28.3 41.9
4–6 16.1 20.6 16.7
7–10 10.4 14.1 7.3
11 13.7 26.0 4.8
Complications of ESRD %
Carpal tunnel syndrome 7.6 11.0a 5.3a
Amyloidosis (2-microglobulin) 7.3 14.9b 1.5b
Parathyroidectomy 8.3 4.2a 4.0b
Annual household income (US $)
$5000 16.6 6.3 15.8
$5000–$10,000 29.2 26.8 27.4
$10,000–$20,000 30.0 27.6 26.1
$20,000–$40,000 18.3 19.7 20.0
$40,000–$75,000 4.8 9.5 8.5
$75,000 1.1 10.2 2.1
Employment statusa %
Employed 26.8 53.3b 16.8a
Disabled 20.0 4.0a 36.6b
aP value  0.05 vs. Europe
bP value  0.0001 vs. Europe
 b  b
 b  b
 b  b
in the unadjusted analysis, but it was still statistically
significant.
DISCUSSION
ESRD patients treated by hemodialysis in Japan re-
ported a much greater burden of kidney disease than
did those in the United States or Europe (Fig. 1). On
the “burden” scale, patients are asked how much they
agree or disagree with four statements: “My kidney dis-
ease interferes too much with my life,” “Too much of
my time is spent dealing with my kidney disease,” “I feel
frustrated dealing with my kidney disease,” and “I feel
like a burden on my family.” The differences between
continents in the “burden” scores were not reduced by
adjustments for the patient characteristics listed in Table
1; in fact, the differences grew wider after adjustments.
Therefore, we cannot attribute the greater burden re-
ported by Japanese patients to differences in comorbid
conditions or in socioeconomic factors. Because there
are no national-norm data for disease-targeted scales,
we cannot distinguish among the many possible explana-
tions for the greater burden reported by Japanese pa-
tients. For example, dialysis practice patterns and the
organization of medical care in Japan might result in
patients spending more time dealing with their kidney
disease. However, culturally mediated differences in the
perception and description of that time could also ac-
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Table 2. Unadjusted and adjusted health-related quality of life (HRQOL) scores
Euro-DOPPS Japan United States
HRQOL Measure Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjusteda
SF-36
Physical functioning 46.9 45.0 65.3b 60.3b 40.8b 42.7c
Role (physical) 34.4 37.2 48.7b 46.5b 31.7 37.6
Bodily pain 57.9 56.4 64.6b 61.4c 59.0 57.1
General health 36.9 36.1 43.4b 40.7b 40.2b 41.0b
Physical component summary 35.5 34.7 41.8b 40.0b 33.1b 33.4c
Vitality 41.9 42.4 53.0b 50.8b 42.9 43.4
Social functioning 62.1 62.2 70.1b 69.2b 62.1 63.5
Role (emotional) 46.1 49.1 53.6c 48.7 51.8c 58.0b
Mental health 59.9 60.8 63.5c 61.8 67.3b 68.2b
Mental component summary 43.2 44.1 44.8c 44.0 46.6b 47.6b
KDQOL
Symptoms, problems 69.9 70.4 75.8b 73.8c 71.1 72.5c
Effects 57.3 57.9 67.7b 66.7b 62.5b 63.1b
Burden 35.4 36.8 28.6b 27.6b 40.8b 42.4b
Work status 25.2 28.5 44.8b 33.0c 20.0b 27.0
Cognitive functioning 73.6 74.3 81.7b 80.0b 77.2b 78.0b
Quality social 77.0 77.2 60.9b 60.6b 75.9 76.0
Sexual functioning 67.7 66.7 65.2 63.3 60.7c 60.5c
Sleep 57.1 58.1 63.2b 61.2c 58.3 59.9c
Social support 73.0 73.0 72.4 72.0 73.1 74.1
Staff encouragement 82.8 80.5 78.5b 79.3 80.6c 78.0c
Satisfaction 71.3 68.9 77.1b 76.2b 70.5 69.2
Average KDQOL 62.4 62.7 65.5b 63.3 62.9 63.7
a Adjusted for patient characteristics in Table 1
bP  0.0001 vs. Euro-DOPPS
cP  0.05 vs. Euro-DOPPS
Table 3. Means of norm-based scores (differences, in standard deviation units, from general-population data)
Euro-DOPPS Japan United States
HRQOL Measure Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjusteda
Physical functioning 1.52 1.65 1.13b 1.34b 1.52 1.48c
Role (physical) 1.22 1.14 1.04c 1.05 1.16 0.98c
Bodily pain 0.57 0.63 0.43c 0.52 0.46c 0.56
General health 1.31 1.37 0.95b 1.06b 1.29 1.27c
Vitality 0.95 0.94 0.62b 0.71b 0.77b 0.76c
Social functioning 0.97 0.97 0.79c 0.80c 0.83c 0.76c
Role (emotional) 1.20 1.12 0.83b 0.96c 0.80b 0.61b
Mental health 0.63 0.57 0.50c 0.57 0.46b 0.41c
a Adjusted for patient characteristics in Table 1
bP  0.0001 vs. Euro-DOPPS
cP  0.05 vs. Euro-DOPPS
count for the greater reported burden. Disentangling an
“actual” burden of kidney disease by some objective
measure (for example, the number of hours spent on
disease-related activities) from patients’ experience of
such a burden is inherently difficult. Nonetheless, the
questions in the “burden” scale of the KDQOL are
clearly focused on subjective factors, that is, on patients’
evaluation of the consequences of their disease. We
therefore believe that the greater burden reported by
Japanese patients should raise clinicians’ awareness of sub-
jective responses to physical disease and of potential cul-
turally mediated differences in those responses [23–27].
As indicated in Table 2, Japanese patients had higher
scores for social functioning and the lowest scores for
quality of social interaction. These apparently paradoxic
findings indicate the need of assessing different aspects
of HRQOL for a better understanding of how the well-
being of hemodialysis patients is affected in different
regions. “Social functioning,” an HRQOL subscale of
the SF-36, assesses patients’ judgments about the extent
to which physical health or emotional problems interfere
with their social activities. “Quality of social interaction,”
an HRQOL subscale of the KDQOL-SF, assesses more
directly patients’ attitudes or behaviors in relation to
people around them, such as the tendencies toward isola-
tion or irritability. In addition to different practice pat-
terns in the hemodialysis treatment itself, cultural differ-
ences may also play a role in the variations observed
across continents.
Other noteworthy results from our study were the
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Fig. 1. Burden scores on three continents.
differences in scores on the physical functioning scale of
the SF-36. The items making up this scale are designed
to measure patients’ self-reported limitations in running,
climbing stairs, walking, putting on clothes, or bathing
on their own. According to their patient questionnaire
responses, Japanese hemodialysis patients were consid-
erably more able to perform these activities than were
hemodialysis patients in the United States and the Euro-
DOPPS countries (Fig. 2). Before attempting to interpret
or explain these differences, we have to consider meth-
odologic factors that could account for the large differ-
ence in scores.
One possibility for the wide difference is that the dif-
ferent versions of the SF-36 used in this study are not
conceptually equivalent. However, in the IQOLA proj-
ect, considerable effort was directed at adapting the
SF-36 for each country in which it was to be used. The
goals of linguistic, semantic, and conceptual equivalence
were rigorously pursued, and the translated versions
were tested and compared [24–27]. Another possibility
is that differences in age, gender, and cultural norms
influenced the HRQOL data, but we believe that norm-
based scoring (Table 3) minimized any differences in
SF-36 scores that might have been caused by those demo-
graphic and cultural factors.
An important result of this study is that Japanese pa-
tients reported both a high level of physical functioning
and a great burden of kidney disease. As described
above, the physical functioning scale measures physical
abilities, but for the “burden” scale patients are asked
whether their kidney disease interferes with life, takes
too much of their time, makes them feel frustrated, or
makes them feel like a burden on their families. Patients
with normal physical abilities may still feel that their
disease imposes a great burden.
After adjustment for age, gender, and comorbid condi-
tions (Table 3), the magnitude of the differences was
much smaller, but the physical functioning scores of the
Japanese patients were still significantly higher. The dif-
ference between patients in Japan and the general popu-
Fig. 2. Physical functioning (PF) score differences from general popu-
lation in standard deviations.
lation of Japan was smaller than the corresponding dif-
ferences between patients and general population in the
United States and Europe.
International differences in HRQOL scores take on ad-
ditional importance when considered in light of HRQOL’s
demonstrated association with mortality risk. In a previ-
ous DOPPS study, lower scores in several measures of
HRQOL, particularly PCS, were found to be strongly
associated with higher risk of death in Japan, Europe,
and the United States [7]. Differences in HRQOL may
in part explain the poorer survival observed for hemodi-
alysis patients treated in the United States than for pa-
tients treated in Japan and Europe.
We adjusted for all of the patient characteristics in
Table 1 to find the adjusted HRQOL scores. Table 1
indicates that Japanese hemodialysis patients have lower
mean hematocrit levels, longer average length of time on
hemodialysis, higher prevalence of complications from
hemodialysis, and higher socioeconomic status. These
variables are likely determinants of physical functioning
scores. For example, the distributions of hematocrit lev-
els and complications of ESRD would tend to make
the differences between countries larger in the analysis.
International differences in erythropoietin use might
also account for some of the differences in hematocrit
and physical functioning, and this topic is now being
studied through analysis of DOPPS data. As a primary
cause of ESRD, diabetic nephropathy is more common
in the United States than in Japan, which could explain
the poorer physical functioning in the United States.
However, diabetic nephropathy is less prevalent in the
Euro-DOPPS countries than in Japan, which seems to
lessen its explanatory power. Socioeconomic factors such
as annual income and work status might also explain
some of the differences in physical functioning scores;
more of the United States patients had low incomes and
were disabled or not employed. These factors may apply
both to unadjusted analyses and to comparisons with
the general population. However, the adjusted analyses
allow comparisons between countries as if all else were
Fukuhura et al: Health-related quality of life in dialysis patients on three continents 1909
equal, that is, as if diabetes, employment, and the other
factors in Table 1 were the same in Japan, the United
States, and the Euro-DOPPS countries. Thus, the ad-
justed analyses overcome most of the limitations re-
sulting from the differences between continents with re-
gard to the factors listed in Table 1.
Other factors may also contribute to or help explain
these international differences. For example, the pre-
viously reported international differences in Kt/V, body
weight, average hours of dialysis, blood flow, and dialyzer
surface area might also be related to the differences in
physical functioning and burden scores, although one
study in Japan found no such relationship [32]. We also
note that international differences in patient compliance
have recently been identified using DOPPS data; skip-
ping and shortening dialysis sessions, more common in
the United States than in Japan or Europe, is associated
with increased risk of mortality and hospitalization, as
well as certain patient characteristics [33]. As another
example, variations in dialysis facility staffing may con-
tribute to these differences, although they are not ana-
lyzed in this paper. Recent analysis of international
DOPPS data indicates that a higher percentage of more
experienced dialysis facility staff is significantly associ-
ated with reduced mortality and other improved out-
comes [abstract; Pifer TB et al, J Am Soc Nephrol 13:
425A, 2002]. Variations in staffing patterns by country
may therefore be another factor contributing to the wide
international differences in physical functioning scores.
Some possible limitations of this study must be noted.
In the linear model, the independent variables might not
have been independent of each other, and their effects
might not have been linear. Furthermore, the data came
from cross-sectional observations of patients at various
times in the course of their disease and treatment. How-
ever, since these analyses were adjusted for time on
dialysis, time after the onset of ESRD should not have
played a role.
We know of no previous study of HRQOL among
hemodialysis patients that allows for a proper compari-
son of patients on these three continents. Our primary
goal was to document clearly any differences in HRQOL
between patients in the United States, the Euro-DOPPS
countries, and Japan, not to dissect these phenomena by
mathematically “explaining” all of the variance among
scores. By drawing attention to differences among the
three groups studied, and by showing that they probably
cannot be attributed to differences in comorbid condi-
tions, demographic factors, or socioeconomic status, we
hope to have indicated some fruitful areas for future
work. With the goal of improving patient-based health
outcomes, we believe that the most worthwhile of the
many possible future studies will be those that focus on
possible differences in the perception of the burden of
kidney disease, and on ways to improve the physical
functioning of patients in the United States and in Eu-
rope by changing clinical practice or health care policy.
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